Vital Therapies, Inc. (VTL) Set to Announce Earnings on Monday

Vital Therapies, Inc. (NASDAQ:VTL) is scheduled to be releasing its earnings data after the market closes on Monday, July 31st. Analysts expect Vital Therapies to post earnings of ($0.35) per share for the quarter.

Vital Therapies (NASDAQ:VTL) last announced its earnings results on Tuesday, May 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.02. During the same quarter in the prior year, the business posted ($0.31) earnings per share. On average, analysts expect Vital Therapies to post $-1.76 EPS for the current fiscal year and $-1.31 EPS for the next fiscal year.

Shares of Vital Therapies, Inc. (NASDAQ VTL) opened at 2.75 on Friday. The stock’s 50 day moving average price is $2.91 and its 200 day moving average price is $3.76. The firm’s market capitalization is $116.07 million. Vital Therapies, Inc. has a 52 week low of $2.25 and a 52 week high of $6.63.

COPYRIGHT VIOLATION WARNING: This news story was first reported by [[site]] and is owned by of [[site]]. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at [[permalink]].

VTL has been the topic of several recent analyst reports. ValuEngine downgraded shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Raymond James Financial, Inc. initiated coverage on shares of Vital Therapies in a report on Thursday, May 18th. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Vital Therapies from a “sell” rating to a “hold” rating in a report on Wednesday, May 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

In other Vital Therapies news, Director Muneer A. Satter bought 10,000 shares of the stock in a transaction that occurred on Tuesday, June 6th. The shares were acquired at an average price of $3.19 per share, with a total value of $31,900.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Muneer A. Satter bought 30,000 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was acquired at an average cost of $3.11 per share, for a total transaction of $93,300.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 108,400 shares of company stock worth $338,153. Insiders own 29.88% of the company’s stock.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.